Table 1.
Investigation of clinical samples for TTSuV1, TTSuV2, PCV1 and PCV2 by PCR
| District |
Detection ratio of TTSuV1 and TTSuV2 |
Detection ratio of PCV1 and PCV2 |
Coinfection of TTSuV and PCV2 |
|||||
|---|---|---|---|---|---|---|---|---|
| TTSuV1 | TTSuV2 | TTSuV1 + TTSuV2 | PCV2 | PCV1 | PCV1 + PCV2 | PCV2 + TTSuV1 | PCV2 + TTSuV1 | |
| Shanghai |
8/12 |
4/12 |
4/12 |
6/12 |
5/12 |
3/12 |
6/12 |
3/12 |
| Jilin |
13/30 |
3/30 |
1/30 |
18/30 |
11/30 |
7/30 |
9/30 |
3/30 |
| Hebei |
3/13 |
1/13 |
0/13 |
2/13 |
8/13 |
2/13 |
0/9 |
0/9 |
| Beijing |
12/19 |
12/19 |
10/19 |
8/19 |
5/19 |
4/19 |
7/19 |
6/19 |
| Liaoning |
2/9 |
3/9 |
1/9 |
1/9 |
2/9 |
1/9 |
1/9 |
0/9 |
| Shandong |
7/12 |
2/12 |
2/12 |
5/12 |
6/12 |
4/12 |
5/12 |
2/12 |
| Hunan |
16/31 |
10/31 |
7/31 |
4/31 |
10/31 |
2/31 |
5/31 |
4/31 |
| Heilongjiang |
76/133 |
43/133 |
25/133 |
51/133 |
62/133 |
29/133 |
33/133 |
11/133 |
| Others |
8/21 |
1/21 |
1/21 |
10/21 |
6/21 |
3/21 |
7/21 |
1/21 |
| Total | 145/280 |
79/280 |
51/280 |
105/280 |
115/280 |
55/280 |
73/280 |
30/280 |
| (51.8%) | (28.2%) | (18.2%) | (37.5%) | (41.1%) | (19.6%) | (26.1%) | (10.7%) | |
Others: the 21 samples were from Sichuan, Hubei, Neimenggu, Jiangsu, Anhui and Zhejiang provinces.